Evidence map›Paper›PMID 40809797›Full record

ArticlePain reports2025

Long-lasting and fast methylglyoxal-scavenging peptide CycK(Myr)R

Paramita Basu, Diogo F S Santos, Nina Gakii, Margaret R Gralinski, Ryan B Griggs, Sebastian Brings, Thomas Fleming, Keiichiro Susuki, Bradley K Taylor

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pain reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Paramita BasuDepartment of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Diogo F S SantosDepartment of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Nina GakiiDepartment of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Margaret R GralinskiDepartment of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Ryan B GriggsDepartment of Neuroscience, Cell Biology, and Physiology, Boonshoft School of Medicine, Wright State University, Dayton, OH, USA.
Sebastian BringsDepartment of Medicine I and Clinical Chemistry and the Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
Thomas FlemingDepartment of Medicine I and Clinical Chemistry, University Hospital of Heidelberg, INF 410, Heidelberg, and the German Center for Diabetes Research (DZD), Neuherberg, Germany.
Keiichiro SusukiDepartment of Neuroscience, Cell Biology, and Physiology, Boonshoft School of Medicine, Wright State University, Dayton, OH, USA.
Bradley K TaylorDepartment of Anesthesiology and Perioperative Medicine, Department of Pharmacology, Pittsburgh Center for Pain Research, and Pittsburgh Project to End Opioid Misuse, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Funding

NEUROPEPTIDERGIC INHIBITION OF SPINAL PAIN TRANSMISSIONR01NS045954 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2002 to 2025
$3.2M
NIDA NIH HHS R01 DA037621NINDS NIH HHS R01 NS045954NINDS NIH HHS R01 NS062306NINDS NIH HHS R01 NS107398
6 · The paper itself

Abstract

Introduction: Pathological levels of methylglyoxal (MG), a reactive dicarbonyl product of glucose, contribute to major neurological complications associated with type II diabetes, including chronic neuropathic pain. Strategies to target elevated MG have included small molecule MG scavengers, but scavenger deficiencies in proteolytic stability and onset of scavenging activity have precluded clinical translation. To address this gap, we developed a long-lasting and highly reactive cyclic peptide CycK(Myr)R Objectives: To test the hypothesis that CycK(Myr)R Methods: We assessed heat hypersensitivity as an index of hyperalgesia, and touch-evoked expression of phosphorylated extracellular signal-regulated kinase as a measure of neuronal activity in spinal cord dorsal horn. Results: We report that a single systemic injection of CycK(Myr)R Conclusion: These studies promote CycK(Myr)R

Indexed as

CycK(Myr)R4Edb/dbDiabetesMethylglyoxalMethylglyoxal scavengerPainful diabetic neuropathy

Identifiers

PMID40809797
PMCPMC12348387

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.